InflaRx (IFRX) Gains from Sales and Divestitures (2018 - 2019)
InflaRx's (IFRX) quarterly Gains from Sales and Divestitures came in at $4494.6 in Q2 2019, down 71.03% year-over-year from $15514.8 in Q2 2018, and up 31.81% quarter-over-quarter from $3409.9 in Q1 2019.
Powered by 
Analysis
InflaRx (IFRX) Gains from Sales and Divestitures (2018 - 2019) Analysis & Trends
InflaRx has disclosed Gains from Sales and Divestitures across 2 years of filings, most recently posting $4494.6 for Q2 2019.
- In Q2 2019, Gains from Sales and Divestitures fell 71.03% year-over-year to $4494.6; the TTM figure through Jun 2019 stood at $18091.7 (changed N/A YoY), while the FY2018 annual figure was $25766.0, changed N/A from the prior year.
- Gains from Sales and Divestitures came in at $4494.6 for Q2 2019 at InflaRx, up from $3409.9 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $15514.8 in Q2 2018 to a low of $3208.5 in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2019 | 4,494.56 |
| Mar 31, 2019 | 3,409.89 |
| Dec 31, 2018 | 3,208.47 |
| Sep 30, 2018 | 6,978.78 |
| Jun 30, 2018 | 15,514.78 |